ExodusPoint Capital Management LP Makes New Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

ExodusPoint Capital Management LP acquired a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 47,421 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,718,000. ExodusPoint Capital Management LP owned about 0.09% of Supernus Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in SUPN. Public Employees Retirement System of Ohio lifted its position in shares of Supernus Pharmaceuticals by 41.6% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 1,253 shares of the specialty pharmaceutical company’s stock worth $42,000 after buying an additional 368 shares during the period. Mendota Financial Group LLC acquired a new stake in shares of Supernus Pharmaceuticals in the 1st quarter valued at $46,000. Tower Research Capital LLC TRC increased its stake in shares of Supernus Pharmaceuticals by 389.7% in the 1st quarter. Tower Research Capital LLC TRC now owns 1,327 shares of the specialty pharmaceutical company’s stock valued at $48,000 after buying an additional 1,056 shares during the period. Group One Trading L.P. boosted its position in shares of Supernus Pharmaceuticals by 103.6% in the 4th quarter. Group One Trading L.P. now owns 1,499 shares of the specialty pharmaceutical company’s stock worth $53,000 after purchasing an additional 43,303 shares during the last quarter. Finally, Point72 Middle East FZE bought a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth $57,000.

Wall Street Analyst Weigh In

SUPN has been the topic of several recent research reports. TheStreet lowered Supernus Pharmaceuticals from a “b+” rating to a “c+” rating in a research report on Friday, May 12th. Piper Sandler reduced their target price on Supernus Pharmaceuticals from $46.00 to $43.00 in a report on Wednesday, July 26th. Finally, StockNews.com lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 16th.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock opened at $32.49 on Friday. The firm has a market cap of $1.77 billion, a price-to-earnings ratio of 44.51 and a beta of 1.01. The stock’s 50-day moving average is $30.86 and its 200-day moving average is $34.25. Supernus Pharmaceuticals, Inc. has a one year low of $29.06 and a one year high of $42.09.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.25). Supernus Pharmaceuticals had a return on equity of 4.86% and a net margin of 6.84%. The company had revenue of $135.56 million for the quarter, compared to the consensus estimate of $143.63 million. During the same quarter in the previous year, the company posted $0.14 EPS. The business’s revenue was down 20.3% on a year-over-year basis. On average, equities analysts expect that Supernus Pharmaceuticals, Inc. will post 1.53 EPS for the current year.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, VP Tami Tillotson Martin sold 8,100 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $32.00, for a total value of $259,200.00. Following the sale, the vice president now owns 85,249 shares in the company, valued at $2,727,968. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 8.76% of the stock is currently owned by corporate insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.